Finding. KSHV vBcl-2, needed for infectious progeny by a function that is not its apoptosis or autophagy block, binds the host Cullin-3 adaptor KLHL9 and pulls it onto mitochondria during lytic reactivation. Binding-dead vBcl-2 mutants fail that colocalization. Knock out KLHL9 and lytic proteins and titers fall; put back an sgRNA-resistant cDNA and both partly recover. vBcl-2 itself is not a detectable KLHL9 ubiquitin substrate. The mitochondrion is the rendezvous, not yet a mapped bioenergetic casualty.
Why this paper matters
Viral Bcl-2 proteins are usually filed under cell-death evasion. Prior work already said KSHV vBcl-2’s lytic requirement is independent of those textbook jobs. Kalt, Ohev, Gelgor Dontsov and colleagues name a host machine that can explain the gap: a BTB-Kelch adaptor for CRL3, relocating to mitochondria with the viral protein.
For a mitochondrial desk this is a localization-and-genetics paper, not an OXPHOS paper. That is still worth a brief. Herpesviruses remodel mitochondria; a ligase adaptor that moves there with an essential lytic protein is a parts-list update.
What they actually measured
HA-vBcl-2 pulldown proteomics in reactivated infected cells, reciprocal co-IP, and ectopic association in uninfected cells. Imaging: KLHL9 leaves a cytoplasmic/perinuclear pattern for a mitochondrial pattern that overlaps HA-vBcl-2. Mutagenesis: N-terminal vBcl-2 determinant; C-terminal Kelch repeats on KLHL9; AlphaFold agreement. Biochemistry: no detectable KLHL9-dependent ubiquitination of vBcl-2. Function: CRISPR KLHL9 loss cuts lytic proteins and infectious progeny; resistant re-expression partially restores.
The non-substrate result is useful. If vBcl-2 is not the ubiquitin target, KLHL9 is either a recruited enzyme for other clients or a structural partner. The abstract does not decide.
How to read the score
Low-to-mid seventies. The mitochondrial claim is relocalization plus genetic necessity for yield. Confidence is medium. There is no respiratory or apoptotic-mitochondrial assay. Score 73, matching the prior rank, as a virus–organelle interaction brief.
What to do with it
Track if you work on KSHV lytic replication, viral Bcl-2 proteins, or mitochondrial ubiquitin adaptors. Pull the IP list and the colocalization mutants. Do not advertise KLHL9 inhibition as an antiviral. The directional implication is that vBcl-2 engages CRL3 machinery at mitochondria to support particle production, by a route that is not vBcl-2 turnover.